

## **A. TRATAMENTO COM HCQ ISOLADA OU ASSOCIADA A AZ PARA COVID-19- ESTUDOS CLINICOS COM RESULTADO DESFAVORÁVEL AO USO E SEM BENEFÍCIO.**

1- Siemieniuk, et al *Drug treatments for covid-19: living systematic review and network meta-analysis*, Reed AC, *BMJ* 2020;370:m2980  
<http://dx.doi.org/10.1136/bmj.m2980>

World Health Organization. *Therapeutics and COVID-19. Living guideline*. 17 Dec 2020. <https://apps.who.int/iris/bitstream/handle/10665/337876/WHO-2019-nCoV-therapeutics-2020.1-eng.pdf>

2-NIH - *Medicamentos antivirais aprovados ou em avaliação para o tratamento de COVID-19. Última atualização: 3 de novembro de 2020*  
<https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/>

3-Omrani et al., *EClinicalMedicine*, doi:10.1016/j.eclinm.2020.100645 (Peer Reviewed)  
*Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.*

4-Kirenga et al., *BMJ Open Respiratory Research*, doi:10.1136/bmjresp-2020-000646 (Peer Reviewed)  
*Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda.*

4-RECOVERY Collaborative Group *Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19.*

<https://www.nejm.org/doi/full/10.1056/NEJMoa2022926>

6-Mitjà et al., *Clinical Infectious Diseases*, ciaa1009, doi:10.1093/cid/ciaa1009  
(Peer Reviewed)

*Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A  
Randomized-Controlled Trial.*

7-Kuderer et al., *Lancet*, June 20, 2020, doi:10.1016/S0140-6736(20)31187-9  
(preprint 5/28) (Peer Reviewed)

*Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.*

8-Auld et al., *Critical Care Medicine*, doi:10.1097/ccm.0000000000004457  
(Peer Reviewed) *ICU and ventilator mortality among critically ill adults with  
COVID-19.*

9-Geleris et al., *NEJM*, May 7, 2020, doi:10.1056/NEJMoa2012410 (Peer  
Reviewed) *Observational Study of Hydroxychloroquine in Hospitalized Patients  
with Covid-19.*

10-Rosenberg et al., *JAMA*, May 11, 2020, doi:10.1001/jama.2020.8630 (Peer  
Reviewed) *Association of Treatment With Hydroxychloroquine or Azithromycin  
With In-Hospital Mortality in Patients With COVID-19 in New York State.*

11-Sbidian et al., *medRxiv*, doi:10.1101/2020.06.16.20132597 (Preprint)  
*Hydroxychloroquine with or without azithromycin and in-hospital mortality or  
discharge in patients hospitalized for COVID-19 infection: a cohort study of  
4,642 in-patients in France.*

12- Peters et al., *Clinical Microbiology and Infection*,  
doi:10.1016/j.cmi.2020.10.004 (Peer Reviewed)  
*Outcomes of persons with coronavirus disease 2019 in hospitals with and  
without standard treatment with (hydroxy)chloroquine.*

<https://pubmed.ncbi.nlm.nih.gov/33068758/>

13-Gupta et al., *JAMA Intern. Med.*, doi:10.1001/jamainternmed.2020.3596  
(Peer Reviewed)

*Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.*

14-Fried et al., *Clinical Infectious Disease*, doi:10.1093/cid/ciaa1268 (Peer Reviewed)

*Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States.*

15-SOLIDARITY Trial Consortium, *NEJM*, doi:10.1056/NEJMoa2023184  
(preprint 10/15) (Peer Reviewed)

*Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results.*

16-Choi et al., *International Journal of Infectious Diseases*,  
doi:10.1016/j.ijid.2020.10.062 (Peer Reviewed)

*Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.*

17-Singer et al., *Annals of the Rheumatic Diseases*, doi:10.1136/annrheumdis-2020-218500 (Letter)

*Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.*

18-Laplana et al., *PLOS ONE*, doi:10.1371/journal.pone.0243598 (Peer Reviewed)

*Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.*

19-Huh et al., *International Journal of Infectious Diseases*,  
doi:10.1016/j.ijid.2020.12.041 (Peer Reviewed)

*Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.*

*20-Molina JM et al, Medicine et Maladies Infectieuses - No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.*

<https://doi.org/10.1016/j.medmal.2020.03.006>

*21-Skipper CP et al Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial - Skipper CP et al, June 2020*

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384270/>

*22-Rajasingham R et al, Clin Infect Dis, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.*

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523161/>

*23-Boulware DR et al, NEJM 2020 - A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. DOI: 10.1056 / NEJMoa2016638*

*24-Borba MGS et al JAMA Netw 2020 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial;*

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499>

*25- Gautret, P et al Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.*

<https://doi.org/10.1016/j.ijantimicag.2020.106241>

26- Guisado-Vasco (Peer Reviewed)

*Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)*  
[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(20\)30335-7/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30335-7/fulltext)

27-Cavalcanti et al., NEJM, July 23, 2020, doi:10.1056/NEJMoa2019014  
(Peer Reviewed)

*Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19*

28- Sarfaraz S et al, Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan  
<https://www.medrxiv.org/content/10.1101/2020.12.28.20248920v1.full.pdf>

29- Sands et al., Inter.Journal of Infectious Diseases, No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19doi:/10.1016/j.ijid.2020.12.060 (Peer Reviewed)

30- Pseudos G et al Corona Virus Disease-19 (COVID-19) in a Veterans Affairs Hospital at Suffolk County, Long Island- New York  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778163/>

31- Barnabas, VR et al, Hidroxicloroquina como profilaxia pós-exposição para prevenir a infecção por Coronavirus 2 com síndrome respiratória aguda: Um ensaio randomizado  
<https://pubmed.ncbi.nlm.nih.gov/33284679/>

32-Nachega et al., *The American Journal of Tropical Medicine and Hygiene*, doi:10.4269/ajtmh.20-1240 (Peer Reviewed)  
*Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.*  
[https://www.ajtmh.org/view/journals/tpmd/103/6/article-p2419.xml?tab\\_body=fulltext](https://www.ajtmh.org/view/journals/tpmd/103/6/article-p2419.xml?tab_body=fulltext)

33- Annie H F et al, *Hidroxicloroquina em pacientes hospitalizados com COVID - 19: Experiência do mundo real avaliando mortalidade.*  
<https://doi.org/10.1002/phar.2467>

**34-** Tehrani et al., *International Journal of Infectious Diseases*, doi:10.1016/j.ijid.2020.10.071 (Peer Reviewed)  
*Risk factors for mortality in adult COVID-19 patients; frailty predicts fatal outcome in older patients.*

35-Self et al., *JAMA*, doi:10.1001/jama.2020.22240 (Peer Reviewed)  
*Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.*  
<https://jamanetwork.com/journals/jama/fullarticle/2772922>

36- Rodriguez-Gonzalez et al., *International Journal of Antimicrobial Agents*, doi:10.1016/j.ijantimicag.2020.106249 (Peer Reviewed)  
*COVID-19 in hospitalized patients in Spain: a cohort study in Madrid.*

37-Alqassieh et al., *F1000Research*, Preprint (Preprint)  
*Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan.*  
<https://f1000research.com/articles/9-1439/v1>

38-Vernaz et al., *Swiss Medical Weekly*, doi:10.4414/smw.2020.20446  
(Peer Reviewed)

*Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.*

<https://smw.ch/article/doi/smw.2020.20446>

39-Chari et al., *Blood*, doi:10.1182/blood.2020008150 (Peer Reviewed)

*Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.*

<https://ashpublications.org/blood/article/136/26/3033/474113/Clinical-features-associated-with-COVID-19-outcome>

40-Gendelman et al., *Autoimmunity Reviews*, 19:7, July 2020,

doi:10.1016/j.autrev.2020.102566 (Peer Reviewed)

*Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent Infection With SARS-CoV-2: Insights From a Large Healthcare Database Analysis.*

41-Gianfrancesco et al., *Annals of the Rheumatic Diseases*, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871 (Peer Reviewed)

*Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.*

42-Gendebien et al., *Annals of the Rheumatic Diseases*,

doi:10.1136/annrheumdis-2020-218244 (Letter)

*Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.*

43- Revollo et al., *Journal of Antimicrobial Chemotherapy*,  
doi:10.1093/jac/dkaa477 (Peer Reviewed)  
*Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers.*  
<https://doi.org/10.1093/jac/dkaa477>

44-Konig et al., *Annals of the Rheumatic Diseases*,  
doi:10.1136/annrheumdis-2020-217690 (Letter)  
*Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.*

45- Ip et al., *PLOS ONE*, doi:10.1371/journal.pone.0237693 (Peer Reviewed) *Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study.*

46- de la Iglesia et al., *medRxiv*, doi:10.1101/2020.08.31.20185314 (Preprint) *Hydroxicloroquine for pre-exposure prophylaxis for SARS-CoV-2.*

47- Huh et al., *International Journal of Infectious Diseases*,  
doi:10.1016/j.ijid.2020.12.041 (Peer Reviewed)  
*Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.*

48- Cassione et al., *Annals of the Rheumatic Diseases*,  
doi:10.1136/annrheumdis-2020-217717 (Letter)  
*COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine*



49- Rentsch et al., *The Lancet Rheumatology*, doi:10.1016/S2665-9913(20)30378-7  
<https://www.medrxiv.org/content/10.1101/2020.09.04.20187781v1> (Peer Reviewed)

*Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.*

50- Li et al., *Research Square*, doi:10.21203/rs.3.rs-119202/v1 (Preprint)  
*Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis.*

## **B. TRATAMENTO COM HCQ ISOLADA OU ASSOCIADA A AZ PARA COVID-19- ESTUDOS CLINICOS COM RESULTADO FAVORÁVEL AO USO .**

1- Gautret P et al, *Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study* Running title: Hydroxychloroquine-Azithromycin and COVID-19 .

<https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf>

2- Guerin V et al, *Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 – Asia Journal of Medicine and Health* <https://doi.org/10.9734/ajmah/2020/v18i730224>

---

3- Lagier J-C et al, *Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine azithromycin and other regimens in Marseille, France: A retrospective analysis – Travel Medicine and Infectious Disease-*

<https://www.sciencedirect.com/science/article/pii/S1477893920302817>

4- Fonseca SNS et al, *Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis - Travel Medicine and Infectious Disease.*

<https://doi.org/10.1016/j.tmaid.2020.101906>

5- Derwand R, et al, *COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study - Internal Journal of Antimicrobials Agents,*

<https://doi.org/10.1016/j.ijantimicag.2020.106214>

6-Ly et al., *International Journal of Antimicrobial Agents,*

doi:10.1016/j.ijantimicag.2020.106219 (preprint 8/21) (Peer Reviewed)

*Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France.*

7- Sánchez-Álvarez et al., *Nefrología*, doi:10.1016/j.nefro.2020.04.002 (Peer Reviewed) *Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN).*

8- Yu et al., *Science China Life Sciences*, 2020 May 15, 1-7,

doi:10.1007/s11427-020-1732-2 (Peer Reviewed)

*Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19.*

9-Huang et al., *National Science Review*, nwa113, doi:10.1093/nsr/nwa113  
(Peer Reviewed)

*Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.*

10-Mikami et al., *J. Gen. Intern. Med.*, doi:10.1007/s11606-020-05983-z (Peer Reviewed)

*Risk Factors for Mortality in Patients with COVID-19 in New York City.*

11-Arshad et al., *Int. J. Infect. Dis.*, July 1 2020, doi:10.1016/j.ijid.2020.06.099  
(Peer Reviewed)

*Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.*

12-Bernaola et al., *medRxiv*, doi:10.1101/2020.07.17.20155960 (Preprint)  
*Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid.*

13- Berenguer et al., *Clinical Microbiology and Infection*,  
doi:10.1016/j.cmi.2020.07.024 (Peer Reviewed)

*Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.*

14-Yu et al., *Science China Life Sciences*, 2020 Aug 3, doi:10.1007/s11427-020-1782-1 (Letter)

*Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.*

15-Yu et al., *Science China Life Sciences*, 2020 May 15, 1-7,  
doi:10.1007/s11427-020-1732-2 (Peer Reviewed)

*Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19.*

16-Pinato et al., *Cancer Discovery*, doi:10.1158/2159-8290.CD-20-0773 (Peer Reviewed)

*Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.*

17-Gonzalez et al., *medRxiv*, doi:10.1101/2020.08.18.20172874 (Preprint)

*The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.*

18-Catteau et al., *Int. J. Antimicrobial Agents*,

doi:10.1016/j.ijantimicag.2020.106144 (Peer Reviewed)

*Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants.*

19-Di Castelnuovo et al., *European J. Internal Medicine*,

doi:10.1016/j.ejim.2020.08.019 (Peer Reviewed)

*Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.*

20-Lauriola et al., *Clinical and Translational Science*, doi:10.1111/cts.12860

(Peer Reviewed)

*Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients.*

21-Shoaibi et al., *medRxiv*, doi:10.1101/2020.09.23.20199463 (Preprint)

*Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.*

22-Ayerbe et al., *Internal and Emergency Medicine*, doi:0.1007/s11739-020-

02505-x (Peer Reviewed) *The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.*

23-Ader et al., *medRxiv*, doi:10.1101/2021.01.08.20248149 (news 10/6)

(Preprint) *Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial.*

24- Ñamendys-Silva et al., *Heart & Lung*, doi:10.1016/j.hrtlng.2020.10.013 (Peer Reviewed) *Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study.*

25-Soto-Becerra et al., *medRxiv*, doi:10.1101/2020.10.06.20208066 (Preprint) *Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru.*

26- Aparisi et al., *medRxiv*, doi:10.1101/2020.10.06.20207092 (Preprint) *Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19.*

27-Coll et al., *American Journal of Transplantation*, doi:10.1111/ajt.16369 (Peer Reviewed) *Covid-19 in transplant recipients: the Spanish experience.*

28-Frontera et al., *Research Square*, doi:10.21203/rs.3.rs-94509/v1 (Preprint) *Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study.*

29-Núñez-Gil et al., *Intern. Emerg. Med.*, doi:10.1007/s11739-020-02543-5 (Peer Reviewed) *Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.*

30-Boari et al, *Biosci. Rep.*, doi:10.1042/BSR20203455 (Peer Reviewed) *Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.*

31-Budhiraja et al., *medRxiv*, doi:10.1101/2020.11.16.20232223 (Preprint) *Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience.*

32-Rodriguez-Gonzalez et al., *International Journal of Antimicrobial Agents*,  
doi:10.1016/j.ijantimicag.2020.106249 (Peer Reviewed)  
*COVID-19 in hospitalized patients in Spain: a cohort study in Madrid.*

33-Signes-Costa et al., *Archivos de Bronconeumología*,  
doi:10.1016/j.arbres.2020.11.012 (Peer Reviewed)  
*Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases.*

34-Taccone et al., *The Lancet Regional Health - Europe*,  
doi:10.1016/j.lanep.2020.100019 (Peer Reviewed)  
*The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium.*

35-Chatterjee et al., *Indian J. Med. Res.*, June 20, 2020,  
doi:10.4103/ijmr.IJMR\_2234\_20 (Peer Reviewed)  
*Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.*

36-Bhattacharya et al., *medRxiv*, doi:10.1101/2020.06.09.20116806 (Preprint)  
*Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers.*

37-Huang et al., *Annals of the Rheumatic Diseases* 2020:79, 1163-1169,  
doi:10.1136/annrheumdis-2020-217425 (Peer Reviewed)  
*Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study.*

38-Ferreira et al., *J. Medical Virology*, July 9, 2020, doi:10.1002/jmv.26286  
(preprint 6/29) (Peer Reviewed) *Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.*

39-Zhong et al., *Lancet Rheumatology*, 10.1016/S2665-9913(20)30227-7  
(Peer Reviewed) COVID-19 in patients with rheumatic disease in Hubei  
province, China: a multicentre retrospective observational study.

40-Khurana et al., *medRxiv*, doi:10.1101/2020.07.21.20159301 (Preprint)  
Prevalence and clinical correlates of COVID-19 outbreak among healthcare  
workers in a tertiary level hospital.

41-Ferri et al., *Clinical Rheumatology*, doi:0.1007/s10067-020-05334-7 (Peer  
Reviewed) COVID-19 and rheumatic autoimmune systemic diseases: report of  
a large Italian patients series.

42-Mathai et al., *J. Marine Medical Society*, doi:10.4103/jmms.jmms\_115\_20  
(Peer Reviewed) Hydroxychloroquine as pre-exposure prophylaxis against  
COVID-19 in health-care workers: A single-center experience.

43-Polat et al., *Medical Journal of Bakirkoy*, 16:3, 280-6,  
doi:10.5222/BMJ.2020.50469 (Peer Reviewed)  
Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A  
Pandemic Hospital Experience.

44-Heras et al., *European Geriatric Medicine*, doi:10.1007/s41999-020-00432-w  
(preprint 9/2) (Peer Reviewed)  
COVID-19 mortality risk factors in older people in a long-term care center.

45-Sulaiman et al., *medRxiv*, doi:10.1101/2020.09.09.20184143 (Preprint)  
The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in  
Ambulatory Care Settings: A Nationwide Prospective Cohort Study.

46-Membrillo de Novales et al., *Preprints 2020*, 2020050057,  
doi:10.20944/preprints202005.0057.v1 (Preprint)  
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-  
19 Patients: An Observational Study.

47-Singh et al., medRxiv, doi:10.1101/2020.05.12.20099028 (Preprint)  
*Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network.*

48-Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926 (Peer Reviewed)  
*Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System.*

49-D'Arminio Monforte et al., *Int. J. Infectious Diseases*,  
doi:10.1016/j.ijid.2020.07.056  
*Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?*

50- Su et al., *BioScience Trends*, doi:10.5582/bst.2020.03340 (Peer Reviewed)  
*Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China.*

### **C. TRATAMENTO IVM ISOLADA OU ASSOCIADA PARA COVID-19- ESTUDOS CLINICOS COM RESULTADO FAVORÁVEL AO USO .**

1-Espitia-Hernandez et al., *Biomedical Research*, 31:5 (Peer Reviewed)  
*Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study*  
<https://www.alliedacademies.org/articles/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html>

2- Shouman et al., *Journal of Clinical and Diagnostic Research*,  
doi:10.7860/JCDR/2020/46795.0000 (Peer Reviewed)  
*Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial*  
<https://www.palmerfoundation.com.au/use-of-ivermectin-as-a-potential-chemoprophylaxis-for-covid-19-in-egypt-a-randomised-clinical-trial/>



3- Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint)  
Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study  
<https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.full-text>

4- Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2 (Preprint)  
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic  
<https://www.researchsquare.com/article/rs-100956/v1>

5- Preliminary meta-analysis of randomized trials of ivermectin to treat SARSCoV-2 infection Authors: Andrew Hill on behalf of the International Ivermectin Project Team\*  
[https://assets.researchsquare.com/files/rs-148845/v1\\_stamped.pdf](https://assets.researchsquare.com/files/rs-148845/v1_stamped.pdf)

## **D. TRATAMENTO IVM ISOLADA OU ASSOCIADA PARA COVID-19- ESTUDOS CLINICOS COM RESULTADOS INCONCLUSIVOS MAS PROMISSORES.**

1- Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7) (Peer Reviewed)  
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial  
[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(20\)30464-8/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext)

2- Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066 (Preprint)  
Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru  
<https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1>

3- Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)  
Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2  
<https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-896543>

4- Niaee et al., *Research Square*, doi:10.21203/rs.3.rs-109670/v1 (Preprint)  
*Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A  
randomized multi-center clinical trial*  
<https://www.researchsquare.com/article/rs-109670/v1>

5- Kirti et al., *medRxiv*, doi:10.1101/2021.01.05.21249310 (Preprint)  
*Ivermectin as a potential treatment for mild to moderate COVID-19: A double  
blind randomized placebo-controlled trial*

<https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1>